000024896 000__ 01506cam\a2200397\i\4500
000024896 001__ 24896
000024896 003__ SzGeWIPO
000024896 005__ 20240708162113.0
000024896 008__ 080201s2008    enk|||||r|||| 00| 0 eng d
000024896 035__ $$a(wipo)0
000024896 035__ $$a(OCoLC)1161333711
000024896 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000024896 050_4 $$aK9$$b.N7477
000024896 08204 $$a346.04805$$219
000024896 084__ $$a72$$qGB
000024896 1001_ $$aMishra, R.,$$eauthor.
000024896 24510 $$aPharma strategies :$$bIn response to business challenges, pharmaceutical companies are developing new patenting, licensing and partnership strategies to exploit their IP rights /$$cMishra, R., Kumar, G.V.S.S.
000024896 264_1 $$aLondon [England] :$$bEuromoney Institutional Investor PLC,$$c2008.
000024896 300__ $$a1 volume ([-16] pages) ;$$c[28] cm.
000024896 336__ $$atext$$btxt$$2rdacontent
000024896 337__ $$aunmediated$$bn$$2rdamedia
000024896 338__ $$avolume$$bnc$$2rdacarrier
000024896 4901_ $$aManaging Intellectual Property,$$x0824-7064 ;$$vGB 72 Oct 2008 No 183, pages 75-59
000024896 650_0 $$aIntellectual property$$zCanada.
000024896 650_0 $$aPatents.
000024896 650_0 $$aIntellectual property.
000024896 650_4 $$aCopyright Law
000024896 650_4 $$aLicensing
000024896 650_4 $$aPharmaceutical Industries
000024896 650_4 $$aPatents
000024896 7001_ $$aKumar, G. V. S. S.
000024896 830_0 $$aManaging Intellectual Property ;$$vGB 72 Oct 2008 No 183, pages 75-59.
000024896 903__ $$aManaging Intellectual Property.
000024896 904__ $$aJournal article
000024896 942__ $$cART$$jGB 72 Oct 2008 No 183$$2ddc
000024896 952__ $$w2009-02-03$$p2009-0128$$u38669$$bMAIN$$10$$kGB 72 $$v2009-02-03$$70$$cMain Library$$yART
000024896 980__ $$aBIB
000024896 999__ $$c27204$$d27204